Literature DB >> 9718074

Hyperforin as a possible antidepressant component of hypericum extracts.

S S Chatterjee1, S K Bhattacharya, M Wonnemann, A Singer, W E Müller.   

Abstract

We demonstrate that the phloroglucinol derivative hyperforin is not only the major lipophilic chemical constituent of the medicinal plant Hypericum perforatum (St. John's wort) but also a potent uptake inhibitor of serotonin (5-HT), dopamine (DA), noradrenaline (NA), GABA and L-Glutamate with IC50 values of about 0.05-0.10 microg/ml (5-HT, NA, DA, GABA) and about 0.5 microg/ml (L-glutamate) in synaptosomal preparations. Furthermore, potencies of two different hypericum extracts in two conventional pharmacological paradigms useful for the detection of antidepressants (behavioral despair, learned helplessness), closely correlate with their hyperforin contents. In addition, most till now known neuropharmacological properties of the clinically used hypericum extracts can also be demonstrated with pure hyperforin. It appears, therefore, that this non-nitrogenous constituent is a possible major active principle responsible for the observed clinical efficacies of the extract as an antidepressant and that it could also be a starting point for drug discovery projects engaged in the search of psychoactive drugs with novel mode of action.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9718074     DOI: 10.1016/s0024-3205(98)00299-9

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  38 in total

1.  Use of hypericum as antidepressant. Valid measure of antidepressant efficacy in primary care is needed.

Authors:  A Thornett
Journal:  BMJ       Date:  2000-04-22

2.  Selected physical and chemical properties of commercial Hypericum perforatum extracts relevant for formulated product quality and performance.

Authors:  S H Kopleman; A NguyenPho; W S Zito; F X Muller; L L Augsburger
Journal:  AAPS PharmSci       Date:  2001

3.  Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients.

Authors:  Steffen Bauer; Elke Störmer; Andreas Johne; Hagen Krüger; Klemens Budde; Hans-Hellmut Neumayer; Ivar Roots; Ingrid Mai
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

Review 4.  Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part I. Regulation and quality.

Authors:  Joanne Barnes
Journal:  Br J Clin Pharmacol       Date:  2003-03       Impact factor: 4.335

Review 5.  Neurotrophic natural products: chemistry and biology.

Authors:  Jing Xu; Michelle H Lacoske; Emmanuel A Theodorakis
Journal:  Angew Chem Int Ed Engl       Date:  2013-12-18       Impact factor: 15.336

6.  Hyperforin activates nonselective cation channels (NSCCs).

Authors:  Kristina Treiber; Andrea Singer; Bettina Henke; Walter E Müller
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

7.  Antidepressant-like effects of Trichilia catigua (Catuaba) extract: evidence for dopaminergic-mediated mechanisms.

Authors:  Maria M Campos; Elizabeth S Fernandes; Juliano Ferreira; Adair R S Santos; João B Calixto
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

Review 8.  Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients.

Authors:  Mario Wurglics; Manfred Schubert-Zsilavecz
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

9.  St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor.

Authors:  L B Moore; B Goodwin; S A Jones; G B Wisely; C J Serabjit-Singh; T M Willson; J L Collins; S A Kliewer
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

10.  Hypericum perforatum L (St John's wort) preferentially increases extracellular dopamine levels in the rat prefrontal cortex.

Authors:  Takashi Yoshitake; Ryuji Iizuka; Shimako Yoshitake; Pia Weikop; Walter E Müller; Sven Ove Ogren; Jan Kehr
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.